Nazir Savji, MD
Interventional Cardiology · Morristown, NJNPI 1215318746
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $32,552 of the $49,997 with a category attached, or 65.1%. Amgen accounts for 61.8% of it on its own, with 36 other manufacturers making up the rest. 2025 is the largest year on record at $22,756, more than ten times the $1,105 reported in 2020.
Across 278 payments — averaging $179.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$31K
- Abbott$7K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$5K
- Boston Scientific$2K
- Medtronic$2K
- Johnson & Johnson$337
- plus $3K from 31 others
What the payments were for
- Speaking & faculty fees$32,55265%
- Grants$1,1052%
- Travel & lodging$4,1878%
- Food & beverage$11,69123%
- Education$4631%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 53 | $30,903 |
| Abbott | 70 | $6,797 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 15 | $4,952 |
| Boston Scientific | 20 | $2,008 |
| Medtronic | 27 | $1,813 |
| Johnson & Johnson | 6 | $337 |
| Abiomed | 3 | $323 |
| Cardiovascular Systems Inc. | 5 | $323 |
| Shockwave Medical, Inc | 3 | $246 |
| Spectrawave, Inc | 1 | $242 |
| Pfizer | 13 | $194 |
| Boehringer Ingelheim | 4 | $174 |
| Novartis | 8 | $170 |
| Teleflex LLC | 1 | $157 |
| Endologix LLC | 1 | $150 |
| Baxter Healthcare | 5 | $126 |
| Novo Nordisk | 7 | $122 |
| Stryker | 1 | $110 |
| Philips North America LLC | 1 | $107 |
| Merck | 5 | $83 |
| AstraZeneca | 5 | $77 |
| Inari Medical, Inc. | 1 | $71 |
| Cardiva Medical, Inc. | 3 | $70 |
| Cordis US CORP. | 1 | $58 |
| Heartflow, Inc. | 1 | $54 |
| Chiesi USA, Inc. | 3 | $45 |
| Sanofi-aventis U.S. LLC | 2 | $39 |
| Esperion Therapeutics, Inc. | 1 | $37 |
| Alnylam Pharmaceuticals Inc. | 2 | $32 |
| Azurity Pharmaceuticals, Inc. | 2 | $31 |
| Amarin Pharma, Inc. | 2 | $27 |
| Impulse Dynamics (USA) Inc. | 1 | $26 |
| Medline Industries LP | 1 | $24 |
| Atricure, Inc. | 1 | $20 |
| Bridgebio Pharma, Inc. | 1 | $19 |
| GSK | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$30,277
- LifeVest$4,726
- OPTIS$1,425
- Ultreon$1,323
- GENERAL - STRUCTURAL$1,105
- DRAGONFLY OPSTAR$921
- SYMPLICITY G3$822
- Diamondback Coronary$650
- XIENCE SKYPOINT$508
- XIENCE SIERRA$396
- Impella$313
- Resolute$280
- HyperVue Imaging System$242
- Starlight Imaging Catheter$242
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$204
- CardioMEMS HF System$176
- COREVALVE EVOLUT R$170
- EnSite Precision Cardiac Mapping System$169
- WOLVERINE CORONARY CUTTING BALLOON$168
- OPTICROSS$163
How this compares
$49,997 in reported general payments places this provider in the 85th percentile of 166 interventional cardiology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 253 | $331,061 |
| Repatha SureclickEvolocumab | 153 | $156,311 |
| XareltoRivaroxaban | 56 | $70,888 |
| MultaqDronedarone Hcl | 44 | $54,056 |
| EntrestoSacubitril/Valsartan | 39 | $38,258 |
| Praluent PenAlirocumab | 34 | $28,423 |
| BrilintaTicagrelor | 19 | $23,651 |
| JardianceEmpagliflozin | 17 | $13,822 |
| Metoprolol Succinate | 460 | $6,644 |
| Rosuvastatin Calcium | 476 | $6,386 |
| Atorvastatin Calcium | 365 | $4,005 |
| Nifedipine ErNifedipine | 60 | $2,968 |
| Telmisartan | 39 | $2,864 |
| Ezetimibe | 92 | $2,856 |
| ClopidogrelClopidogrel Bisulfate | 188 | $2,432 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $194 | $331,061253 claims |
| Johnson & JohnsonXarelto | $337 | $70,88856 claims |
| Sanofi-aventis U.S. LLCMultaq | $39 | $54,05644 claims |
| NovartisEntresto | $170 | $38,25839 claims |
| AstraZenecaBrilinta | $77 | $23,65119 claims |
| Boehringer IngelheimJardiance | $174 | $13,82217 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 166 interventional cardiology providers in New Jersey.
Other interventional cardiology in Morristown
- Dimitrios KarmpaliotisMorristown$129K
- Amirali MasoumiMorristown$45K
- Mark BlumMorristown$41K
- Craig RosenMorristown$26K
- John CosmiMorristown$15K
- David FreilichMorristown$15K
- Ankitkumar PatelGlen Ridge$408K
- Ziad AbbudOcean$360K
- Ramin HastingsHasbrouck Heights$295K
- Michael LimHackensack$215K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.